XH001 Injection

DRUG3 trials

Sponsors

Jia Wei, Beijing GoBroad Hospital, Shenzhen Xinhe Biomedical

Conditions

Advanced Gastric CancerBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)Gastric Cancer (GC)Gastrointestinal CancerHepatocellular Carcinoma (HCC)Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1

Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

RecruitingNCT07298200

Jia WeiAdvanced Gastric Cancer

Start: 2025-12-26End: 2029-11-01Target: 18Updated: 2026-02-25

Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer

RecruitingNCT07329894

Beijing GoBroad HospitalGastrointestinal Cancer

Start: 2026-02-01End: 2029-10-01Target: 18Updated: 2026-02-12

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

RecruitingNCT07594964

Shenzhen Xinhe BiomedicalBiliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC) +1

Start: 2025-08-25End: 2030-06-30Target: 48Updated: 2026-05-19